TrialBritish journal of cancer2016

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.

W Janni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.